Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived.
A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and much cheaper than alternative products used by smokers seeking to quit, such as Champix.
more information on www.ft.com
